Thursday, November 07, 2019 2:47:41 PM
"On October 21, 2019, Bionano Genomics, Inc. (the “Company”) entered into an underwriting agreement with Oppenheimer & Co. Inc., as representative of the several underwriters named in Schedule I thereto, relating to the public offering, issuance and sale of 10,013,600 shares of its common stock and, to certain investors, pre-funded warrants to purchase 10,923,958 shares of its common stock, and accompanying common warrants to purchase up to an aggregate of 20,937,558 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $0.86 and $0.859 for each pre-funded warrant and accompanying common warrant. The pre-funded warrants are immediately exercisable at a price of $0.001 per share of common stock. The common warrants are immediately exercisable at a price of $0.86 per share of common stock and will expire five years from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The offering closed on October 23, 2019.
The gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses, were approximately $18.0 million. The Company anticipates using the net proceeds from the offering primarily for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters and capital expenditures."
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13697161&RcvdDate=10/23/2019&CoName=BIONANO%20GENOMICS,%20INC&FormType=8-K&View=html
Recent BNGO News
- Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 12:15:32 PM
- Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy • GlobeNewswire Inc. • 05/21/2024 12:00:00 PM
- Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 09:27:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:09:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:28 PM
- Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress • GlobeNewswire Inc. • 05/08/2024 08:01:00 PM
- Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference • GlobeNewswire Inc. • 04/30/2024 08:05:00 PM
- Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/04/2024 05:44:35 PM
- Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:48:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:47:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:46:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:44:40 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:26:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:23:48 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM